Literature DB >> 16614505

Surgical resection of recurrent lung cancer in patients following curative resection.

Hyoung Soo Kim1, Hoseok I, Yong Soo Choi, Kwhanmien Kim, Young Mog Shim, Jhingook Kim.   

Abstract

We reviewed our experience with resection of recurrent lung cancer to evaluate the benefit and risk of the procedure. From December 1994 to December 2003, 29 consecutive patients underwent pulmonary resections for recurrent lung cancer. The mean duration from the first resection to second surgery was 25.4+/-15.1 months for the definite 2nd primary lung cancer (n=20) and 8.9+/-5.7 months for metastatic lung cancer (n=9). The procedures at the second operations were completion-pneumonectomy in 11 patients, lobectomy in 5 patients, wedge resection in 12 patients and resection and anastomosis of trachea in 1 patient. Morbidity was observed in 6 (21%) of the patients and the in-hospital mortality was two patients (7%) after the repeated lung resection. Tumor recurrence after reoperation was observed in 14 patients (48%). The actuarial 5-yr survival rate was 69% and the 5-yr disease free rate following reoperation was 44%. No significant difference was found in overall survival and disease free survival between the 2nd primary lung cancer group and the metastatic lung cancer group. The recurrence rate following reoperation was significantly different between the wedge resection group and lobectomy/completion pneumonectomy group (p=0.008), but the survival rate was not significantly different (p=0.41). Surgical intervention for recurrent lung cancers can be performed with acceptable mortality and morbidity. If tolerable, completion pneumonectomy or lobectomy is recommended for resection of recurrent lung cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16614505      PMCID: PMC2733995          DOI: 10.3346/jkms.2006.21.2.224

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  17 in total

1.  Iterative surgical resections for local recurrent and second primary bronchogenic carcinoma.

Authors:  L Voltolini; P Paladini; L Luzzi; C Ghiribelli; M Di Bisceglie; G Gotti
Journal:  Eur J Cardiothorac Surg       Date:  2000-11       Impact factor: 4.191

Review 2.  Positron emission tomography (PET) of non-small cell lung cancer.

Authors:  U Haberkorn
Journal:  Lung Cancer       Date:  2001-12       Impact factor: 5.705

3.  Completion pneumonectomy: current indications, complications, and results.

Authors:  T Fujimoto; G Zaboura; S Fechner; L Hillejan; T Schröder; A Marra; T Krbek; M Hinterthaner; D Greschuchna; G Stamatis
Journal:  J Thorac Cardiovasc Surg       Date:  2001-03       Impact factor: 5.209

4.  The management of second primary lung cancers. A single centre experience in 15 years.

Authors:  Tarek M Aziz; Rasheed A Saad; Jonathan Glasser; Ali N Jilaihawi; Dhruva Prakash
Journal:  Eur J Cardiothorac Surg       Date:  2002-03       Impact factor: 4.191

5.  Surgical management of metachronous bronchial carcinoma.

Authors:  C Doddoli; P Thomas; O Ghez; R Giudicelli; P Fuentes
Journal:  Eur J Cardiothorac Surg       Date:  2001-06       Impact factor: 4.191

6.  Multiple primary lung cancers.

Authors:  N Martini; M R Melamed
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

7.  Completion pneumonectomy: experience in eighty patients.

Authors:  J F Regnard; P Icard; P Magdeleinat; B Jauffret; E Farés; P Levasseur
Journal:  J Thorac Cardiovasc Surg       Date:  1999-06       Impact factor: 5.209

8.  Surgery for second lung cancers.

Authors:  J W Asaph; J F Keppel; J R Handy; E C Douville; A C Tsen; G Y Ott
Journal:  Chest       Date:  2000-12       Impact factor: 9.410

9.  Completion pneumonectomy for non-small cell lung cancer: experience with 59 cases.

Authors:  A Terzi; A Lonardoni; G Falezza; P Scanagatta; A Santo; G Furlan; F Calabrò
Journal:  Eur J Cardiothorac Surg       Date:  2002-07       Impact factor: 4.191

10.  Subsequent pulmonary resection for bronchogenic carcinoma after pneumonectomy.

Authors:  Jessica S Donington; Daniel L Miller; Charles C Rowland; Claude Deschamps; Mark S Allen; Victor F Trastek; Peter C Pairolero
Journal:  Ann Thorac Surg       Date:  2002-07       Impact factor: 4.330

View more
  6 in total

Review 1.  Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.

Authors:  Swaroop Revannasiddaiah; Priyanka Thakur; Bhaskar Bhardwaj; Sridhar Papaiah Susheela; Irappa Madabhavi
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  Completion pneumonectomy: outcomes for benign and malignant indications.

Authors:  Varun Puri; Andrew Tran; Jennifer M Bell; Traves D Crabtree; Daniel Kreisel; Alexander S Krupnick; G Alexander Patterson; Bryan F Meyers
Journal:  Ann Thorac Surg       Date:  2013-05-03       Impact factor: 4.330

3.  Iterative surgical resections in non-small cell lung cancer.

Authors:  Ahmet Ucvet; Serkan Yazgan; Ozgur Samancilar; Soner Gursoy; Ahmet Emin Erbaycu; Berna Komurcuoglu
Journal:  Kardiochir Torakochirurgia Pol       Date:  2022-01-09

4.  Exhaled Breath Temperature Home Monitoring to Detect NSCLC Relapse: Results from a Pilot Study.

Authors:  Giovanna Elisiana Carpagnano; Todor A Popov; Giulia Scioscia; Nicoletta Pia Ardò; Donato Lacedonia; Mario Malerba; Pasquale Tondo; Piera Soccio; Domenico Loizzi; Maria Pia Foschino Barbaro; Francesco Sollitto
Journal:  Biomed Res Int       Date:  2022-02-21       Impact factor: 3.411

5.  Activation of Akt pathway by transcription-independent mechanisms of retinoic acid promotes survival and invasion in lung cancer cells.

Authors:  Alejandro García-Regalado; Miguel Vargas; Alejandro García-Carrancá; Elena Aréchaga-Ocampo; Claudia Haydée González-De la Rosa
Journal:  Mol Cancer       Date:  2013-05-21       Impact factor: 27.401

6.  Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer.

Authors:  Kyung Hwa Lee; Yong Chan Ahn; Hongryull Pyo; Jae Myoung Noh; Seung Gyu Park; Tae Gyu Kim; Eonju Lee; Heerim Nam; Hyebin Lee; Jong-Mu Sun; Jin Seok Ahn; Myung-Ju Ahn; Keunchil Park
Journal:  Cancer Res Treat       Date:  2018-09-11       Impact factor: 4.679

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.